The Importance of RAD51 Testing in Early-Stage Breast Cancer

Biomarkers have become increasingly important in cancer treatment in recent years. Developing personalized treatment strategies for early-stage breast cancer is a critical goal, helping patients avoid unnecessarily aggressive treatment and offering more targeted approaches. A new study by Villacampa and colleagues, published in Clinical Cancer Research, suggests that the RAD51 biomarker test could play an important role in guiding treatment decisions for patients with early-stage breast cancer.

What Is RAD51?

RAD51 is a protein that plays a key role in DNA repair and homologous recombination. It maintains genomic integrity, particularly by repairing double-strand DNA breaks. Active during the S and G2 phases of the cell cycle, RAD51 interacts with DNA-repair proteins such as BRCA1 and BRCA2. Mutations can disrupt DNA repair mechanisms and increase the risk of tumor development, particularly in cancers such as breast and ovarian cancer associated with BRCA gene mutations. RAD51 is therefore an important subject of research in cancer biology and targeted therapies.

The Role of Homologous Recombination in DNA Repair

Homologous recombination is a cellular mechanism used to repair DNA damage and preserve genetic information. During this process, the cell repairs DNA by exchanging information between homologous chromosomes with similar DNA sequences. This maintains genetic integrity and supports healthy cell proliferation. DNA recombination is the rearrangement or alteration of DNA within a cell.

There are different types:

Homologous recombination: organizes genetic material and repairs DNA damage through exchanges between similar DNA sequences.

Site-directed recombination: is used to alter specific genes or DNA regions and plays an important role in genetic engineering.

Non-homologous recombination: occurs when different DNA regions join and can lead to genetic changes.

These processes play critical roles in DNA repair, genetic engineering, and cellular function.

Below is a simplified diagram of DNA repair through homologous recombination. BRCA1, RPA, RAD51, BRCA2, and PALB2 are molecules involved in this repair pathway.

HRD testing is recommended for all patients with ovarian or triple-negative breast cancer to determine their suitability for a new generation of cancer drugs called PARP inhibitors.

For more information on homologous recombination, visit ' What Is Homologous Recombination Deficiency, How Is It Tested, and Why Does It Matter in Cancer? '.

Study Background

Dr. Violeta Serra, head of the Experimental Therapeutics Group at the Vall d’Hebron Institute of Oncology, explains that the study's main aim was to identify biomarkers capable of selecting patients who might benefit from less aggressive treatments than chemotherapy. New methods that could enable individualized breast cancer treatment are being investigated, and the RAD51 protein stands out as an important biomarker in this context. 

The RAD51 Test and Study Findings

A new test has been developed using the RAD51 protein as a functional biomarker of the homologous recombination repair mechanism. Researchers assessed whether identifying deficiencies in cancer-cell DNA repair pathways could predict which neoadjuvant treatment patients would respond to better.

The researchers analyzed tumor samples from the randomized GeparOla clinical trial. That trial compared the PARP inhibitor olaparib with carboplatin-based chemotherapy in patients with early-stage HER2-negative breast cancer and homologous recombination deficiency (HRD). Study leader Dr. Guillermo Villacampa, head of the Biostatistics Group at the Vall d’Hebron Institute of Oncology, said the post-hoc analysis evaluated the RAD51 test's ability to predict response to neoadjuvant treatment.

Among the 90 patients evaluated, RAD51 protein levels correlated with functional homologous recombination deficiency (HRD) in 80%. Patients receiving a PARP inhibitor as neoadjuvant treatment who had HRD identified by RAD51 testing had a pathological complete response rate of 66.7%. By contrast, the rate fell to 22.2% in patients with a negative RAD51 test. In a multivariable analysis including various clinical and pathological factors, tumor-infiltrating lymphocytes, and treatment type, the RAD51 test remained significantly associated with pathological complete response and retained its prognostic capacity.

Conclusion and Future Research

Dr. Serra emphasized that the findings support the potential use of RAD51 testing to personalize treatment strategies in early-stage breast cancer.

Another study author, Dr. Judith Balmaña, said the SOLTI-led RADIOLA clinical trial was designed to evaluate the validity of the RAD51 biomarker test in advanced breast cancer as well. Its results could be combined with existing data to further refine patient selection criteria.

Biomarker-focused studies of this kind could make cancer treatment more targeted, spare patients unnecessary chemotherapy, and optimize treatment responses.